Decision support for PICC Line placement in patients with CKD ca. 2023 #Nephpearls #VascularAccessPearls #NephSky #VisualGraphic by @brianrifkin.bsky.social 👉🏼 pubmed.ncbi.nlm.nih.gov/34218708/

Acute Hypercalcemia: Treatment #Nephpearls #NephSky 👉🏼 shop.lww.com/Handbook-of-...

Check out GlomPedia: The essential guide to glomerular diseases at your fingertips #GlomConHawaii 🌊 #Nephpearls #NephSky 📌 #GlomPedia is your 🆓 go-to eBook library for glomerular diseases Apple App Store apps.apple.com/us/app/glomp... Google Play play.google.com/store/apps/d...

Opinion-based approach to genetic 🧬 testing in adult-onset FSGS #GlomConHawaii 🌊 #Nephpearls #NephSky 📌 Note that viral- and drug-associated forms of FSGS are usually excluded by clinical and serologic evaluation 👉 pubmed.ncbi.nlm.nih.gov/29321142/

The one and only @kidneyboy.bsky.social representing #NephJC at #GlomConHawaii 🌊 #NephSky

Updated review of membranous nephropathy: Target 🎯 antigens ca. 2024 #Nephpearls 👉 pubmed.ncbi.nlm.nih.gov/38681023/

Pillars of #IgAN Treatment #GlomConHawaii 🌊 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/38398259/

Its generic name "budesonide" does not distinguish targeted release formulation (TRF) of budesonide from other formulations (nasal spays, inhalers, etc.) so the name "Nefecon" was used to refer to it in the @kdigo.org guidelines for IgA Nephropathy #IgAN #GlomConHawaii 🌊 #Nephpearls #NephSky

Clinical Endpoints for Glomerular Diseases from @hjanders.bsky.social #GlomConHawaii 🌊 #Nephpearls #NephSky

Kidney Health Guidance on Potassium and Phosphorus Food Additives ca. 2025 from @asnpublications.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/40965988/

Phase 3 clinical trials open in 2025 evaluating new treatments for IgA Nephropathy #IgAN from @kdigo.org #Nephpearls #NephSky 👉🏼 kdigo.org/guidelines/i...

Treatment targets 🎯 in IgA Nephropathy #IgAN and the positioning of drugs ca. 2025 from @kdigo.org #Nephpearls #NephSky 📌 Proteinuria >/= 0.5 g/day (or equivalent) ~ at risk of progressive loss of kidney function 👉🏼 kdigo.org/guidelines/i...

On September 18, @kdigo.org will release The 2025 Clinical Practice Guideline for the Management of IgA Nephropathy (IgAN) and IgA Vasculitis (IgAV) #Nephpearls #NephSky

Clinical management of hyperkalemia ca. 2020 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/33160639/

CKM (Cardiovascular-Kidney-Metabolic) Alphabet soup: GDMT in CKD from Daniel Edmonston #Nephpearls #NKFClinicals 🇺🇸 #Cardiorenal #NephSky

Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes (T2D) ca. 2025 from @asnpublications.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/40327845/

Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled #Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial ca. 2025 from @asnpublications.bsky.social @escardio.bsky.social #Nephpearls #NephSky #ESCCongress 👉 journals.lww.com/jasn/fulltex...

Although often used interchangeably, dehydration & volume depletion are not the same 📌 Dehydration refers to “loss of total body water” (leads to hypertonicity) 📌 Volume depletion refers to an ECFV deficit #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/21705120/

Looking forward to participating in Makati Medical Center's Section of Nephrology 9th Postgraduate Course #Nephpearls #MMCNephrology #AKIinICU #NephSky Secure your slot now: 👉 forms.gle/anrYd5t4GsHq...

Asymptomatic hyponatremia in peritoneal dialysis patients: an algorithmic approach ca. 2014 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/25145783/

PD Catheter Inflow Failure #Nephpearls #NephSky ✅ Heparinized Saline 20 mL flush ✅ Heparin 500 units/L ✅ KUB ✅ t-PA 2 mgs/ 40 mL NS

Proposed update to current treatment paradigm for dysregulated vitamin D metabolism in CKD ca. 2025 from @asnpublications.bsky.social #Nephpearls #CKDMBD #NephSky 👉 pubmed.ncbi.nlm.nih.gov/40857105/

Characteristics of patients and facility of peritoneal dialysis in Korea 🇰🇷: Results from the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS) Korea ca. 2025 from @pdi-journal.bsky.social @ispd.org #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/38738926/

APOL1 Mediated Kidney Disease (AMKD): Clinical approach to genetic testing ca. 2025 from @kidneymed.bsky.social @glomcon.org #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/40837248/

Did you know that there’s a connection between James Bond 007 and Finerenone ? #Nephpearls #NephSky 👉🏼 cardiorenal.medicalaffairs.bayer.com/clinical-tri...

Dialysis Timeline: How it started ⏩ How it's going #Nephpearls #NephSky 👉 link.springer.com/book/10.1007...

On Hydralazine and ANCA-GN #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/10693882/ 👉 pubmed.ncbi.nlm.nih.gov/33857570/ 👉 shop.lww.com/Handbook-of-...

I often see Hydralazine being prescribed as a first-line anti-HTN agent 🫣 📌 These are not first line and when used in treating resistant #hypertension, they may be added “only if” already on a BB (or bradycardic) and loop diuretic #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/40811516/

The latest 2025 #Hypertension Guidelines are out 📣 #Nephpearls #NephSky 📌 On checking Office and Home BP 👉🏼 pubmed.ncbi.nlm.nih.gov/40811516/

The latest 2025 #Hypertension Guidelines are out 📣 #Nephpearls #NephSky 📌 Use of risk-based thresholds for initiation of BP treatment 📌 BP thresholds and recommendations for treatment and follow-up 📌 Screening for features suggesting secondary hypertension 👉🏼 pubmed.ncbi.nlm.nih.gov/40811516/

Diagnosis and Management of Osteoporosis in Advanced Kidney Disease: A Review ca. 2022 from @ajkd.bsky.social #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/34419519/

Urine sodium (Urine Na) levels post-saline infusion in differentiating non-edematous hyponatremia ca. 2025 #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/40775013/

Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus ca. 2020 #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/32387127/

Transplant 101: Approach to the living kidney donor candidate with hypertension #Nephpearls #WTC2025 🇺🇸 #NephSky 👉🏼 link.springer.com/book/10.1007...

Post-transplant hypertension: Pathophysiology #HTNSecrets #Nephpearls #NephSky 👉 shop.elsevier.com/books/hypert...

IgA Nephropathy #IgAN: An Overview of the Clinical Trials ca. 2025 from @saynanorouzi.bsky.social #Nephpearls #NephSky www.kidneymedicinejournal.org/article/S259...

What is the target intact PTH level in patients with CKD who are not on dialysis? from @kdigo.org #Nephpearls #CKDMBD #NephSky 👉 kdigo.org/guidelines/c...

Quick Guide to Converting ESAs ca. 2023 from @amyaimei.bsky.social #Nephpearls #NephSky 👉🏼 www.renalfellow.org/2023/05/02/q...

Light Chain MGUS Calculator #Onconephrology 🦀 #Nephpearls #NephSky H/T @sabinekaram.bsky.social 📱 istopmm.com/lcmgus/ 👉 pubmed.ncbi.nlm.nih.gov/36100605/

Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases ca. 2024 from @asnpublications.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/39292519/

Kidney Health Guidance on the Outpatient Management of Patients with Dialysis-Requiring AKI ca. 2025 from @asnpublications.bsky.social #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/40014384/

Algorithm for kidney biopsy 🔬 evaluation in patients suspected to have MGRS ca. 2019 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/30510265/

Severe AKI in the ICU: Management ca. 2025 #Nephpearls #AKIinICU #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/40578821/

Association of Dialysate Bicarbonate with Arrhythmia in the Monitoring in Dialysis Study ca. 2025 from @asnkidney.bsky.social #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov?term=Associa...

The Clinical Utility of Genetic 🧬 Testing in the Diagnosis and Management of Adults with CKD ca. 2023 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/37794564/

Saline vs balanced solutions: Which is a better solution? #Nephpearls #NephSky 👉 shop.lww.com/Handbook-of-...

Algorithmic approach to Peritoneal Dialysis (PD) Catheter OUTFLOW FAILURE #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/20630641/

Peritoneal Dialysis (PD) Catheter INFLOW FAILURE #Nephpearls #NephSky ✅ Heparinized Saline 20 mL flush ✅ Heparin 500 units/L ✅ KUB ✅ t-PA 2 mgs/ 40 mL NS

Sparsentan: a dual endothelin and angiotensin II receptor antagonist (DEARA) approved for IgA nephropathy (IgAN) ca 2025 from @doctorgates.bsky.social @hecmagsmd.bsky.social @annagaddy.bsky.social #Nephpearls #NephSky www.tandfonline.com/doi/full/10....

Management of the Hemodialysis Patient with Catheter-Related Bloodstream (CRBSI) Infection ca. 2019 #Nephpearls #NephSky 👉🏼 pubmed.ncbi.nlm.nih.gov/30837242/